Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.

Abstract

Abstract:A pathogenic implication of cathepsin K (Cath K) and its inhibitor -cystatin C (Cyst C) occur to be of growing importance in the mechanisms of tumor invasiveness in lung cancer. This study was conducted to investigate the prognostic role and the effects of chemotherapy on serum Cath K and Cyst C (ELISA) in patients with advanced stage nonsmall cell lung cancer (NSCLC). The study entered 40 patients (32 men) and 15 healthy volunteers (control group). Peripheral blood samples were taken before and after four cycles of chemotherapy. The mean serum Cyst C levels were significantly higher in patients with advanced NSCLC than in controls (p=0.003). The levels of Cath K in serum of NSCLC are comparable to those in controls. No correlation was found between Cath K and Cyst C concentrations and the histological type and staging of lung cancer. Patients with T4-stage had a lower level of Cyst C, than those with T2 (p=0.033). No correlation was found between the concentrations of Cath K, Cyst C and the effect of chemotherapy. However, Cyst C level positively correlated with serum creatinine concentration (R=0.535; p=0.005) in patients who responded to chemotherapy and with patient's age (R=0.456; p=0.018) in whole group. When the cut-off values of serum Cath K and Cyst C (23.35 pmol/l, 1.29 mg/l, respectively) were used, the prognoses of high and low groups were not different. Concluding, patients with lung cancer have a higher serum concentration of Cyst C compared to healthy people. In our opinion, determination of Cath K and Cyst C concentrations has no clinical significance in the prognosis of the survival time in lung cancer.

Serum levels of cystatin C in elderly lung cancer patients

“…Thus, the extent of malignancy may be thought to affect Cys-C levels. In the present study, no significant difference was found in the serum levels of Cys-C between advanced and non-advanced lung cancer patients, which was consistent with the findings in 40 non-small cell lung cancer patients reported by Naumnik et al (16). Whether the significant correlation between serum Cys-C levels and tumor extent is dependent on the original site of the cancer is beyond our current knowledge.…”

“…In addition, results of recent studies have shown a significant correlation between serum Cys-C levels and malignant progression in colorectal cancer, melanoma and ovarian cancer (11)(12)(13), although earlier studies reported that serum Cys-C levels were not affected by the presence of malignancies (14,15). With regard to serum Cys-C levels in patients with lung cancer, there is only one report by Naumnik et al (16). These authors reported that no correlation exists between serum Cys-C levels and staging of the disease (16).…”

“…With regard to serum Cys-C levels in patients with lung cancer, there is only one report by Naumnik et al (16). These authors reported that no correlation exists between serum Cys-C levels and staging of the disease (16).…”

Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy

“…In vitro , CysC secretion is not affected by cisplatin [18], but the effect of other anti-emetics on CysC production or release is unknown. In vitro , CysC transcription is increased in numerous cancer cell lines [38, 39], and in some patients with malignancy there is increased pCysC [40, 41], which has generally correlated with burden of disease [42, 43]. …”

Cysteine peptidases and their inhibitors in breast and genital cancer.

“…In a lymph node negative population, cathepsin B protein and activity were better prognostic indicator for diseasefree survival than in the total patient population. On the other hand the expression of cathepsin B in gastric carcinoma is associated with lymph node metastasis but not with postoperative survival [20], the negative cathepsin D staining was related with one year survival in advanced squamous cell carcinoma [21] and cathepsin K and cystatin C were not predictors of the survival in patients with advanced non-small-cell lung cancer during chemotherapy [22]. In Harcbeck and al.…”